Tocqueville Asset Management’s Bicycle Therapeutics BCYC Stock Holding History

Tocqueville Asset Management’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,600	Closed	-$89.2K	–	553
2025 Q4	$89.2K	Buy	12,600 +300	+2%	+$2.21K	﹤0.01%	572
2025 Q3	$95.2K	Sell	12,300 -10,600	-46%	-$80K	﹤0.01%	543
2025 Q2	$159K	Buy	22,900 +4,600	+25%	+$36.6K	﹤0.01%	524
2025 Q1	$155K	Buy	18,300 +3,600	+24%	+$42.4K	﹤0.01%	504
2024 Q4	$206K	Sell	14,700 -700	-5%	-$15K	﹤0.01%	522
2024 Q3	$349K	Sell	15,400 -2,000	-11%	-$46.1K	0.01%	446
2024 Q2	$352K	Sell	17,400 -50	-0.3%	-$1.13K	0.01%	440
2024 Q1	$435K	Sell	17,450 -5,900	-25%	-$125K	0.01%	424
2023 Q4	$422K	Buy	+23,350	New	+$386K	0.01%	415

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

GSK plc London $602M AUM

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Tocqueville Asset Management's BCYC Position: Q1 2026 in Review

Tocqueville Asset Management sold out of Bicycle Therapeutics (BCYC) in Q1 2026, closing a stake of 12,600 shares — an estimated $89.2K sold.

Tocqueville Asset Management first reported a position in BCYC in Q4 2023 and held it in 9 quarters. The position peaked at $435K in Q1 2024. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

Tocqueville Asset Management reported no remaining Bicycle Therapeutics position as of Q1 2026 after selling out during the quarter.
Tocqueville Asset Management sold 12,600 Bicycle Therapeutics shares in Q1 2026, an estimated $89.2K.
Tocqueville Asset Management first reported a position in Bicycle Therapeutics in Q4 2023 and held it in 9 quarters.
Tocqueville Asset Management's Bicycle Therapeutics position peaked at $435K in Q1 2024.
98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Tocqueville Asset Management's 13F filing for Q1 2026, filed 12 May 2026.